Can Orum Therapeutics crack one of AML’s hardest problems with ORM-1153? AACR 2026 data spark fresh attention
Orum Therapeutics unveiled AACR 2026 data for ORM-1153 in AML. Read why the CD123 degrader strategy could matter for efficacy and tolerability.